AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00501397
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01784978
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg pd
Trial: NCT01784978
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg pd
Trial: NCT00790023
Drug: 80 mcg Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
Trial: NCT00790023
Drug: 160 mcg Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
Trial: NCT02547350
Drug: pharmorubicin or pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmorubicin 50mg pirarubicin 30mg
Trial: NCT01087905
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If \> 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day
Trial: NCT01087905
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
Trial: NCT00152646
Drug: placebo, aspirine, clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00879645
Drug: Sodium Sulfide
RxNorm normalized name: Sodium Sulfide
DrugBank: Sodium sulfide (DB11159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
Trial: NCT00879645
Drug: Sodium Sulfide
RxNorm normalized name: Sodium Sulfide
DrugBank: Sodium sulfide (DB11159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
Trial: NCT00879645
Drug: Sodium Sulfide
RxNorm normalized name: Sodium Sulfide
DrugBank: Sodium sulfide (DB11159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
Trial: NCT00665470
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks
Trial: NCT03110120
Drug: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Trial: NCT03110120
Drug: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Trial: NCT03110120
Drug: 0.5% levobupivacaine injectable solution with physiological saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serratus plane block realized with 20 ml of injectable solution of physiological saline
Trial: NCT03110120
Drug: 0.5% levobupivacaine injectable solution with physiological saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local infiltration of the wound with 20 ml of injectable solution of physiological saline
Trial: NCT00273026
Drug: salmeterol xinafoate/fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03974035
Drug: Second infiltration pre-extubation with ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
Trial: NCT01506713
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel Tablets 75 mg
Trial: NCT01540240
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
Trial: NCT01540240
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
Trial: NCT03644212
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
Trial: NCT00279825
Drug: CD-LD CR
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator containing 50 mg carbidopa and 200 mg levodopa
Trial: NCT01549002
Drug: Intravenous Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
Trial: NCT01421264
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg capsules by mouth
Trial: NCT02344732
Drug: Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02344732
Drug: Homatropine 2% eye drops thrice daily
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02344732
Drug: Oxygen gas
RxNorm normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00835991
Drug: Glyburide/Metformin 5 mg/500 mg Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 x 5 mg/500 mg, single-dose fed
Trial: NCT02832973
Drug: Furosemide,
RxNorm normalized name: Furosemide, 80 mg oral tablet
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide 20-40 mg
Trial: NCT02832973
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 5-10 mg
Trial: NCT02832973
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bisoprolol 5-10 mg
Trial: NCT00004259
Drug: CCNU
RxNorm normalized name: CCNU
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
Trial: NCT03061981
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
Trial: NCT03061981
Drug: DA-1241
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
Trial: NCT03775421
Drug: macitentan 10 mg
RxNorm normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: macitentan 10 mg, film-coated tablet, oral use
Trial: NCT00856388
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00856388
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00829673
Drug: Dexmethylphenidate Hydrochloride
RxNorm normalized name: Dexmethylphenidate Hydrochloride
DrugBank: Dexmethylphenidate (DB06701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg Tablet
Trial: NCT00836667
Drug: Sertraline hydrochloride 100 mg Tablets
RxNorm normalized name: sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 100 mg, single-dose fed
Trial: NCT01796730
Drug: bambuterol
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
Trial: NCT01022463
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine 5 mg BId for 4 weeks
Trial: NCT01445951
Drug: Insulin Aspart in combination with a basal insulin
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injectable insulin
Trial: NCT01271283
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT01022463
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg od for 4 weeks
Trial: NCT00272779
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg Oral capsules for 96 weeks
Trial: NCT00272779
Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet with 300 mg - 200 mg once a day for 96 weeks.
Trial: NCT00272779
Drug: LPV
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg (3 133mg capsules) BID for 96 weeks
Trial: NCT00440518
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
Trial: NCT00440518
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
Trial: NCT01588795
Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
Trial: NCT00561015
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Trial: NCT00561015
Drug: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
Trial: NCT00003015
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003015
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03270735
Drug: Snake venom thrombin (Treatment)
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snake venom thrombin
Trial: NCT04414800
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intranasal ketamine
Trial: NCT01565733
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
Trial: NCT02500121
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
Trial: NCT00301951
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301951
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00301951
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301951
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00256737
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02955615
Drug: ILT-101
RxNorm normalized name: ILT-101
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ...
Trial: NCT04539639
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
Trial: NCT04539639
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
Trial: NCT04539639
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
Trial: NCT00650702
Drug: Latanoprost-PPDS
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Trial: NCT00650702
Drug: Latanoprost-PPDS
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Trial: NCT00650702
Drug: Latanoprost-PPDS
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Trial: NCT00750633
Drug: Moxifloxacin otic solution
RxNorm normalized name: moxifloxacin Ophthalmic Solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Trial: NCT00750633
Drug: Dexamethasone phosphate otic solution
RxNorm normalized name: dexamethasone sodium phosphate Otic Solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Trial: NCT01437397
Drug: Aclidinium Bromide/Formoterol Fumarate
RxNorm normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
Trial: NCT01437397
Drug: Aclidinium Bromide/Formoterol Fumarate
RxNorm normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
Trial: NCT01437397
Drug: Aclidinium Bromide
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhaled Aclidinium 400 μg, twice per day
Trial: NCT01437397
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Formoterol 12 μg, twice per day
Trial: NCT01616407
Drug: 3,4-Methylenedioxymethamphetamine
RxNorm normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg per os, single dose
Trial: NCT01616407
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg per os, single dose
Trial: NCT01505569
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles
Trial: NCT01505569
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age \>36 mos.) approx. hour 75 on days -5, -4, and -3
Trial: NCT01505569
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles
Trial: NCT01505569
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
Trial: NCT01505569
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
Trial: NCT01505569
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age \>36 mos.) approx. hour 72 on days -5, -4, and -3
Trial: NCT01505569
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
Trial: NCT01505569
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
Trial: NCT00163657
Drug: Daclizumub
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-rejection drug
Trial: NCT00163657
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti rejection drug
Trial: NCT00163657
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti rejection drug
Trial: NCT00163657
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti rejection drug